Clinical Trials on Glioblastoma Multiforme in Spain

Total 79 results

Medical Research Council
Merck Sharp & Dohme LLC; Aarhus University Hospital; NCRI Clinical Studies Groups and other collaborators

Unknown

Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475

Glioblastoma

United States, Italy, Belgium, Germany, Poland, Russian Federation, Spain, Switzerland, Ukraine, United Kingdom
Universitätsmedizin Mannheim
University of California, Los Angeles; Carl Zeiss Meditec AG

Recruiting

Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme (INTRAGO-II)

Glioblastoma

Korea, Republic of, Germany, Canada, Spain, United States, Brazil, China, United Kingdom
Apollomics Inc.

Recruiting

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA)

Gastric Cancer | Pancreatic Cancer | NSCLC | Lung Cancer | Brain Tumor | Glioblastoma Multiforme | Advanced Cancer | Colon Cancer | Solid Tumors | Thyroid Cancer | Renal Cancer | Gastroesophageal Junction Adenocarcinoma | EGFR Gene Mutation | MET Amplification | HGF | MET Alteration | MET Fusion | Exon 14 Skipping

United States, Spain, France, United Kingdom, Taiwan, Australia, Finland, Italy, Singapore, Hungary, Canada, Puerto Rico, Russian Federation
Celgene

Active, not recruiting

A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma

Glioblastoma

Spain, United States, Denmark, Italy, Netherlands, Norway, Sweden
Proximagen, LLC

Terminated

Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM)

Solid Tumors (Phase 1) | Relapsed/Recurrent GBM (Phase 2)

United States, Spain
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer

Prostate Cancer | Brain and Central Nervous System Tumors

United States, Spain
Instituto de Investigación Sanitaria de la Fundación...
Effice Servicios Para la Investigacion S.L.

Active, not recruiting

Clinical Trial to Evaluate Safety and Efficacy of Cell Therapy in Patients With Cicatricial Conjuntivitis. (CELOPHIN)

Stevens-Johnson Syndrome | Lyell Syndrome | Pemphigoid | Chronic Conjunctivitis

Spain
Eli Lilly and Company

Active, not recruiting

A Study in Recurrent Glioblastoma (GB)

Glioblastoma

United States, Germany, Spain, Belgium, Italy, Australia, Canada, France, Poland
European Organisation for Research and Treatment...

Completed

Nitrocamptothecin in Treating Patients With Glioblastoma Multiforme

Brain and Central Nervous System Tumors

France, Spain, Belgium, Netherlands, Switzerland, Italy
Grupo Español de Investigación en Neurooncología
Pfizer

Completed

Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.

Glioblastoma | Brain Tumor, Recurrent

Spain
Pfizer

Completed

Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme

Glioblastoma

South Africa, Italy, Russian Federation, United States, Canada, Germany, Australia, Austria, Croatia, Czech Republic, France, India, Spain
Hoffmann-La Roche

Completed

A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma

Glioblastoma

United Kingdom, Austria, Croatia, France, Italy, Spain, Turkey, Romania, Portugal, Canada, Greece, Sweden, Bulgaria, Estonia, Latvia
Hoffmann-La Roche

Completed

A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent Glioblastoma

Glioblastoma

United States, United Kingdom, France, Italy, Spain, Germany, Canada, Switzerland
European Organisation for Research and Treatment...
Pfizer

Completed

Radiation Therapy and Temsirolimus or Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

Brain and Central Nervous System Tumors

United Kingdom, Switzerland, Belgium, Italy, Germany, France, Netherlands, Spain
Eli Lilly and Company

Completed

Enzastaurin Versus Lomustine in Glioblastoma

Glioblastoma

Germany, Italy, United States, Belgium, Netherlands, India, Austria, Spain, Poland, Australia, France, Mexico, United Kingdom, Canada
Hoffmann-La Roche

Completed

A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma

Glioblastoma

United States, United Kingdom, Belgium, Denmark, Korea, Republic of, Poland, Spain, Canada, Sweden, Russian Federation, Australia, Greece, Portugal, France, Netherlands, New Zealand, Switzerland, Germany, Hong Kong, Hungary, Israel and more
Novartis Pharmaceuticals

Terminated

Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma

c-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Del. of PTEN or PTEN Neg. by IHC, c-Met Ampli. by FISH, INC280, BKM120, Buparlisib; Recurrent GBM

Spain, Switzerland, Germany, United States, Netherlands
Isarna Therapeutics GmbH

Terminated

Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma (SAPPHIRE)

Glioblastoma | Anaplastic Astrocytoma

Spain, Taiwan, Korea, Republic of, United States, Hungary, Germany, Argentina, Brazil, India, Canada, Austria, France, Mexico, Poland, Russian Federation, United Kingdom
AbbVie
Radiation Therapy Oncology Group

Completed

A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)

Glioblastoma | Gliosarcoma

United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Colombia, Czechia, France, Germany, Hong Kong, Ireland, Israel, Italy, Korea, Republic of, Mexico, Netherlands, New Zealand, Portugal, Russian Federation, Singapor... and more
Novartis Pharmaceuticals

Terminated

Ceritinib Rare Indications Study in ALK+ Tumors

Glioblastoma | Anaplastic Large Cell Lymphoma | Inflammatory Myofibroblastic Tumor | Tumors With Aberrations in ALK

France, Czechia, Italy, Spain, Korea, Republic of, Thailand, Israel, Denmark
AbbVie
European Organisation for Research and Treatment of Cancer - EORTC

Completed

Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas (INTELLANCE-2)

Glioblastoma

United States, Australia, Austria, Belgium, Canada, Czechia, Finland, France, Germany, Hungary, Ireland, Italy, Korea, Republic of, Mexico, Netherlands, Poland, Singapore, Spain, Switzerland, Taiwan, United Kingdom
Incyte Corporation

Active, not recruiting

Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209)

Glioblastoma | Adult-type Diffuse Gliomas

United States, Spain, Italy, United Kingdom, Germany, Japan, France, Netherlands, Denmark
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Active, not recruiting

An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) (CheckMate548)

Brain Neoplasms

United States, Australia, Austria, Belgium, Canada, Denmark, France, Germany, Israel, Italy, Japan, Netherlands, Norway, Poland, Russian Federation, Spain, Sweden, Switzerland, United Kingdom
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) (CheckMate 498)

Brain Cancer

United States, Canada, Belgium, Spain, Australia, Netherlands, United Kingdom, Denmark, Norway, Japan, Sweden, France, Poland, Austria, Germany, Israel, Italy, Russian Federation, Switzerland
Celgene

Completed

Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma

Lymphoma | Lymphoma, Large B-Cell, Diffuse | Glioblastoma | Multiple Myeloma | Primary Central Nervous System Lymphoma | Pleiotropic Pathway Modifier

United States, Spain, Belgium, France, Italy
PharmaMar

Recruiting

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

Glioblastoma | Pancreatic Adenocarcinoma | Neuroendocrine Tumors | Advanced Solid Tumors | Mesothelioma | SCLC | Gastric Carcinoma | Endometrial Carcinoma | Colorectal Carcinoma | Gastroenteropancreatic Neuroendocrine Tumor | Epithelial Ovarian Carcinoma | Soft Tissue Sarcoma (Excluding GIST)

United States, Spain, France, Germany, Italy, Switzerland
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)

Glioblastoma | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Advanced Solid Tumors | Triple Negative Breast Cancer | Biliary Tract Cancers

United States, Argentina, Australia, Canada, Chile, Colombia, France, Germany, Israel, Italy, Korea, Republic of, Russian Federation, Spain, Switzerland, Taiwan, Thailand, United Kingdom
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors

Glioblastoma | Astrocytoma | Anaplastic Astrocytoma | Anaplastic Ganglioglioma | Anaplastic Pleomorphic Xanthoastrocytoma | Ganglioglioma | Pleomorphic Xanthoastrocytoma | Diffuse Astrocytoma | Anaplastic Oligodendroglioma | Pilocytic Astrocytoma | Gangliocytoma | Central Neurocytoma | Oligodendroglioma, Childhood and other conditions

United States, Italy, Japan, Germany, Spain, France, Canada, Australia, Brazil, Israel, Russian Federation, Argentina, United Kingdom, Finland, Belgium, Denmark, Czechia, Sweden, Switzerland, Netherlands
Novartis Pharmaceuticals

Recruiting

Pediatric Long-Term Follow-up and Rollover Study

Glioblastoma | Astrocytoma | Anaplastic Astrocytoma | Neurofibromatosis Type 1 | Anaplastic Ganglioglioma | Anaplastic Pleomorphic Xanthoastrocytoma | Ganglioglioma | Pleomorphic Xanthoastrocytoma | Diffuse Astrocytoma | Anaplastic Oligodendroglioma | Pilocytic Astrocytoma | Gangliocytoma | Central Neurocytoma | Oligodendroglioma... and other conditions

United States, Belgium, Spain, Denmark, Germany, Czechia, Italy, Australia, Russian Federation, France, Brazil, Netherlands, Japan, Canada, Finland, Sweden, United Kingdom, Argentina, Israel

Clinical Trials on Glioblastoma Multiforme in Spain

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations